Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma

Journal of Clinical Oncology

Volumn 32, Issue 29, 2014, Pages e98-e100

  Shih, Kent C ^a   Shastry, Mythili ^b   Williams, Jeffrey T ^a   Jelsma, Peter F ^a   Abram, Steven R ^a   Ayyanar, Kanyalakshmi ^c   Burris, Howard A ^b   Infante, Jeffrey R ^b  

^a SAINT THOMAS HOSPITAL   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DABRAFENIB; GADOLINIUM; GEMFIBROZIL; GLIAL FIBRILLARY ACIDIC PROTEIN; IRINOTECAN; NEUROFILAMENT PROTEIN; SYNAPTOPHYSIN; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME;

ADD ON THERAPY; ADULT; ALERTNESS; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CRANIOTOMY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENERAL CONDITION DETERIORATION; GLIA CELL; GLIOMA; HEADACHE; HOSPITAL ADMISSION; HUMAN; LIMITED MOBILITY; MALE; MALIGNANT TRANSFORMATION; MITOSIS RATE; MONOTHERAPY; NECK PAIN; NERVE CELL DIFFERENTIATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE HYDROCEPHALUS; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; THERAPY EFFECT; TREATMENT DURATION; TUMOR VOLUME; VISUAL DISORDER; YOUNG ADULT; BRAIN NEOPLASMS; GANGLIOGLIOMA; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GANGLIOGLIOMA; HUMANS; IMIDAZOLES; MAGNETIC RESONANCE IMAGING; MALE; OXIMES; YOUNG ADULT;

EID: 84906792112     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.6852     Document Type: Article

References (13)

1. Wetmore C: Location, location, location: Gene expression studies of brainstem ganglioglioma-A rare tumor in a very rare location. Pediatr Blood Cancer 59:1153-1154, 2012
2. Luyken C, Blümcke I, Fimmers R, et al: Supratentorial gangliogliomas: Histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. Cancer 101:146-155, 2004
3. El Khashab M, Gargan L, Margraf L, et al: Predictors of tumor progression among children with gangliogliomas: Clinical article. J Neurosurg Pediatr 3:461-466, 2009
4. Lee CC, Wang WH, Lin CF, et al: Malignant transformation of supratentorial ganglioglioma. Clin Neurol Neurosurg 114:1338-1342, 2012
5. Lang FF, Epstein FJ, Ransohoff J, et al: Central nervous system gangliogliomas: Part 2. Clinical outcome. J Neurosurg 79:867-873, 1993
6. Kincaid PK, El-Saden SM, Park SH, et al: Cerebral gangliogliomas: Preoperative grading using FDG-PET and 201Tl-SPECT. Am J Neuroradiol 19:801-806, 1998
7. Nixon KT, Hudgins PA, Davis PC, et al: Delayed intracranial hemorrhage in children after suboccipital craniectomy. AJR Am J Roentgenol 163:897-900, 1994
8. Horbinski C, Kofler J, Yeaney G, et al: Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 21:564-574, 2011
9. Pandita A, Balasubramaniam A, Perrin R, et al: Malignant and benign ganglioglioma: A pathological and molecular study. Neuro Oncol 9:124-134, 2007
10. Dougherty MJ, Santi M, Brose MS, et al: Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12:621-630, 2010
11. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
12. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
13. Long GV, Trefzer U, Davies MA, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095, 2012.